The synthetic method of favipiravir

Abstract

The invention discloses a method for synthesizing favipiravir, which specifically comprises using DMSO in combination with a microchannel reactor, or a micromixer and a microchannel reactor, and is composed of 6-fluoro-3-hydroxy-2-cyanopyrazine in NaOH and H 2 O 2 Favipiravir was prepared under the conditions. The synthesis method of the present application uses a microchannel reactor, which has high mass transfer efficiency and can significantly improve the reaction conversion rate, thereby reducing pollution and loss; the method of the present application has a short reaction time, the entire reaction time is between 1-10 minutes, and the production efficiency is high; The continuous reaction is realized, the production efficiency is improved, and the labor cost is reduced. And because the reactant hydrogen peroxide is dangerous as an oxidant, the method has high safety.

Description

technical field

[0001] The invention relates to a drug synthesis technology, in particular to a method for synthesizing favipiravir. Background technique

[0002] Favipiravir (favipiravir, T-705, trade name Avigan, 1), chemical name 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, is a targeted RNA-dependent drug developed by Japan's Toyama Chemical Pharmaceutical Company A novel broad-spectrum antiviral drug of RNA polymerase (RdRp) was approved for marketing in Japan in March 2014 for the treatment of novel and recurrent influenza. The mechanism of action of favipiravir is mainly that after entering the body, under the action of a series of cellular phosphokinases, it generates the form of its nucleoside analog triphosphate, thereby interfering with the replication and transcription of the virus. The study found that favipiravir has good inhibitory activity against various RNA viruses in vitro or in vivo, and is expected to be developed and applied to the treatment of various vi...

Images